Ensign Peak Advisors Inc Buys Shares of 113,934 Immunome, Inc. (NASDAQ:IMNM)

Ensign Peak Advisors Inc purchased a new position in Immunome, Inc. (NASDAQ:IMNM) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 113,934 shares of the company’s stock, valued at approximately $1,379,000.

A number of other large investors also recently modified their holdings of IMNM. Sofinnova Investments Inc. grew its position in Immunome by 10.3% in the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company’s stock valued at $7,934,000 after buying an additional 61,284 shares in the last quarter. Primecap Management Co. CA lifted its stake in shares of Immunome by 26.2% in the 2nd quarter. Primecap Management Co. CA now owns 268,800 shares of the company’s stock worth $3,252,000 after acquiring an additional 55,800 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Immunome by 105.0% in the 2nd quarter. Renaissance Technologies LLC now owns 93,300 shares of the company’s stock worth $1,129,000 after acquiring an additional 47,782 shares during the period. Quest Partners LLC bought a new position in shares of Immunome in the second quarter valued at approximately $81,000. Finally, Arizona State Retirement System increased its stake in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after acquiring an additional 918 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IMNM. Piper Sandler cut their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome has a consensus rating of “Buy” and an average price target of $29.00.

Insider Transactions at Immunome

In related news, Director Jean Jacques Bienaime purchased 7,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the transaction, the director now directly owns 16,615 shares of the company’s stock, valued at approximately $231,613.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Jean Jacques Bienaime acquired 7,000 shares of Immunome stock in a transaction on Friday, August 16th. The stock was bought at an average cost of $13.94 per share, with a total value of $97,580.00. Following the completion of the purchase, the director now owns 16,615 shares of the company’s stock, valued at $231,613.10. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares in the company, valued at $760,090.76. The disclosure for this sale can be found here. 8.60% of the stock is owned by insiders.

Immunome Price Performance

NASDAQ IMNM opened at $14.38 on Friday. Immunome, Inc. has a 12 month low of $6.93 and a 12 month high of $30.96. The company has a market capitalization of $862.35 million, a P/E ratio of -1.90 and a beta of 1.77. The company’s 50 day simple moving average is $14.58 and its 200 day simple moving average is $15.71.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The company had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.62 million. On average, analysts anticipate that Immunome, Inc. will post -1.92 earnings per share for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.